For the past decade, pharmaceutical companies have increasingly used voluntary licenses to allow generic production of patented antiretroviral drugs for People Living with HIV/AIDS in poor countries. However, these licenses have not been pursued optimally from a public health standpoint. This paper will comment on the current efforts of global health institutions and propose a path forward to ensure that voluntary licenses are pursued in a strategic, access-maximizing manner.